Arzerra Receives Approval in Japan

Arzerra Receives Approval in Japan

Company Announcement

  *Arzerra(r) approved in Japan for relapsed / refractory CLL
  *Genmab to receive DKK 20 million milestone payment from GSK

COPENHAGEN, Denmark, March 25, 2013 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) and GlaxoSmithKline (GSK) announced today the approval of
Arzerra (ofatumumab) by the Japanese Ministry of Health, Labor and Welfare
(MHLW) for use in patients with relapsed / refractory CD20-positive chronic
lymphocytic leukemia (CLL).The approval triggers a milestone payment of DKK
20 million from GSK to Genmab.

"We are pleased that patients in Japan will now have access to Arzerra. Japan
is another important market for Arzerra and commercialization continues on
track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.

This milestone payment is included in Genmab's 2013 financial guidance.

About ofatumumab

Ofatumumab is a human monoclonal antibody which targets an epitope on the CD20
molecule encompassing parts of the small and large extracellular loops
(Teeling et al 2006). Ofatumumab is being developed under a co-development and
commercialization agreement between Genmab and GlaxoSmithKline.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra^(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^(r); the
Y-shaped Genmab logo^(r); HuMax^(r); HuMax-CD20^(r); DuoBody^(r), HexaBody^TM
and UniBody^(r). Arzerra^(r) is a trademark of GlaxoSmithKline.

Company Announcement no. 10
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark